沙利度胺治疗肝癌的实验研究

目的研究沙利度胺对肝癌的治疗作用。方法采用小鼠肝癌移植性模型。观察沙利度胺对实体型和腹水型肿瘤的治疗作用。结果沙利度胺按每日200mg／kg连续给药10d，能明显抑制肝癌实体型肿瘤的生长，不降低小鼠血细胞数及淋巴细胞增殖；对腹水型肿瘤小鼠虽无明显生命延长作用，但沙利度胺与阿霉素联合用药对肝癌实体型及腹水型均有协调抗肿瘤作用，且可阻止阿霉素造成的小鼠血细胞减少、免疫功能降低。沙利度胺日剂量200mg／kg能明显增加肿瘤组织坏死，促进肿瘤组织边缘淋巴细胞侵润。结论沙利度胺对小鼠肝癌有确切治疗作用，与阿霉素联合用药效果更好。

Experimental study of thalidomide for treatment of murine hepatocellular carcinoma

OBJECTIVE: To study the therapeutic effect of thalidomide (Tha) on murine hepatocellular carcinoma. METHODS: In murine transplanted hepatoma model, thalidomide was administered intragastrically alone (200 mg/kg daily for 10 days) or in combination with doxorubicin. The antitumor activity of Tha was observed in solid and ascitic tumor models. RESULTS: Tha induced significant growth inhibition of solid hepatoma without obvious toxicity on peripheral blood cells and lymphocyte proliferation. Although Tha alone had no effect on the survival of mice with ascitic tumor, it showed a synergistic antitumor activity in combination with doxorubicin (Dox) in both solid and ascitic tumor models. Moreover, Tha reduced Dox-induced cytopenia and immunosuppression. Histological analysis of Tha-treated tumors revealed remarkably enhanced tumor necrosis and lymphocyte infiltration on the edge of tumor tissues. CONCLUSION: Tha has definite therapeutic effect on murine hepatoma, and the combination with Dox shows an enhanced therapeutic potential.